Wu Jie, Zhu Yiqing, Jiang Yunfei, Cao Yaoping
Department of Obstetrics and Gynecology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.
Gynecol Endocrinol. 2008 Jul;24(7):392-8. doi: 10.1080/09513590802217027.
Polycystic ovary syndrome (PCOS) is a major endocrine abnormality that affects women of reproductive age. Oral contraceptive pills are usually the first choice of treatment for PCOS when fertility is not desired. Metformin, an insulin-sensitizing drug, has been shown to improve such metabolic abnormality. Aim. To compare the effects of a contraceptive pill in combination with metformin on the clinical, endocrine and metabolic parameters in obese and non-obese patients with PCOS.
Sixty PCOS patients (25 obese, 35 non-obese) were enrolled in this prospective clinical study. PCOS was defined according to the Rotterdam criteria. Patients were randomized to oral treatment with Diane35 (35 microg ethinyl estradiol plus 2 mg cyproterone acetate), metformin or a combination of Diane35/metformin for 3 months. Body mass index (BMI), waist-to-hip ratio (WHR), Ferriman-Gallwey (FG) score, leuteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, fasting insulin and glucose/insulin ratio were measured at baseline and at the end of treatment.
Diane35 resulted in a higher reduction of FG score in both obese and non-obese PCOS patients compared with metformin. Menstrual regularity was restored in all PCOS patients treated with Diane35 compared with only 28% of those receiving metformin. Metformin significantly decreased BMI and WHR in obese patients (p < 0.05). Testosterone levels decreased in all three groups. LH levels and LH/FSH ratio decreased with Diane35 and Diane35/metformin in both obese and non-obese patients. Metformin significantly decreased fasting insulin concentrations (p < 0.05 and p < 0.01) and increased the insulin sensitivity (p < 0.05) in both obese and non-obese PCOS patients, while no significant changes were observed in the Diane35 group. In addition, insulin levels also decreased (p < 0.05) in the Diane35/metformin group.
Our data show that a combination of metformin and contraceptive pill may be more effective in suppressing the hyperandrogenemia of obese and non-obese PCOS patients than metformin alone and may reduce insulin levels more than contraceptive pill alone. Hence, combined treatment may become a more effective therapeutic option for PCOS.
多囊卵巢综合征(PCOS)是一种影响育龄女性的主要内分泌异常疾病。当不期望生育时,口服避孕药通常是PCOS治疗的首选。二甲双胍,一种胰岛素增敏药物,已被证明可改善此类代谢异常。目的:比较避孕药联合二甲双胍对肥胖和非肥胖PCOS患者临床、内分泌和代谢参数的影响。
60例PCOS患者(25例肥胖,35例非肥胖)纳入这项前瞻性临床研究。PCOS根据鹿特丹标准定义。患者被随机分为口服达英35(35微克炔雌醇加2毫克醋酸环丙孕酮)、二甲双胍或达英35/二甲双胍联合治疗3个月。在基线和治疗结束时测量体重指数(BMI)、腰臀比(WHR)、费里曼-盖尔韦(FG)评分、黄体生成素(LH)、卵泡刺激素(FSH)、睾酮、空腹胰岛素及血糖/胰岛素比值。
与二甲双胍相比,达英35使肥胖和非肥胖PCOS患者的FG评分降低幅度更大。与仅28%接受二甲双胍治疗的患者相比,所有接受达英35治疗的PCOS患者月经恢复规律。二甲双胍显著降低肥胖患者的BMI和WHR(p<0.05)。三组患者的睾酮水平均下降。肥胖和非肥胖患者使用达英35及达英35/二甲双胍后LH水平及LH/FSH比值下降。二甲双胍显著降低肥胖和非肥胖PCOS患者的空腹胰岛素浓度(p<0.05和p<0.01)并提高胰岛素敏感性(p<0.05),而达英35组未观察到显著变化。此外,达英35/二甲双胍组的胰岛素水平也下降(p<0.05)。
我们的数据表明,二甲双胍与避孕药联合使用在抑制肥胖和非肥胖PCOS患者高雄激素血症方面可能比单独使用二甲双胍更有效,且在降低胰岛素水平方面可能比单独使用避孕药更有效。因此,联合治疗可能成为PCOS更有效的治疗选择。